| The experimental power of FR900359 to study Gq-regulated biological processes R Schrage, AL Schmitz, E Gaffal, S Annala, S Kehraus, D Wenzel, ... Nature communications 6 (1), 10156, 2015 | 341 | 2015 |
| Tissue-resident memory CD8+ T cells promote melanoma–immune equilibrium in skin SL Park, A Buzzai, J Rautela, JL Hor, K Hochheiser, M Effern, N McBain, ... Nature 565 (7739), 366-371, 2019 | 316 | 2019 |
| Translation reprogramming is an evolutionarily conserved driver of phenotypic plasticity and therapeutic resistance in melanoma P Falletta, L Sanchez-del-Campo, J Chauhan, M Effern, A Kenyon, ... Genes & development 31 (1), 18-33, 2017 | 222 | 2017 |
| Targeting CD39 in cancer reveals an extracellular ATP-and inflammasome-driven tumor immunity XY Li, AK Moesta, C Xiao, K Nakamura, M Casey, H Zhang, J Madore, ... Cancer discovery 9 (12), 1754-1773, 2019 | 203 | 2019 |
| Amplification of N-Myc is associated with a T-cell-poor microenvironment in metastatic neuroblastoma restraining interferon pathway activity and chemokine expression JP Layer, MT Kronmüller, T Quast, D Boorn-Konijnenberg, M Effern, ... Oncoimmunology 6 (6), e1320626, 2017 | 109 | 2017 |
| CD155 on tumor cells drives resistance to immunotherapy by inducing the degradation of the activating receptor CD226 in CD8+ T cells M Braun, AR Aguilera, A Sundarrajan, D Corvino, K Stannard, S Krumeich, ... Immunity 53 (4), 805-823. e15, 2020 | 95 | 2020 |
| Adoptive T cell therapy targeting different gene products reveals diverse and context-dependent immune evasion in melanoma M Effern, N Glodde, M Braun, J Liebing, HN Boll, M Yong, E Bawden, ... Immunity 53 (3), 564-580. e9, 2020 | 32 | 2020 |
| Altered Notch signaling in Dowling-Degos disease: additional mutations in POGLUT1 and further insights into disease pathogenesis DJ Ralser, H Takeuchi, G Fritz, FB Basmanav, M Effern, S Sivalingam, ... The Journal of investigative dermatology 139 (4), 960, 2019 | 16 | 2019 |
| Epigallocatechin‐3‐gallate exhibits anti‐inflammatory effects in a human interface dermatitis model—implications for therapy C Braegelmann, D Niebel, S Ferring‐Schmitt, T Fetter, J Landsberg, ... Journal of the European Academy of Dermatology and Venereology 36 (1), 144-153, 2022 | 13 | 2022 |
| The experimental power of FR900359 to study Gq-regulated biological processes. Nat Commun 6: 10156 R Schrage, AL Schmitz, E Gaffal, S Annala, S Kehraus, D Wenzel, ... | 10 | 2015 |
| Targeting CD39 in cancer reveals an extracellular ATP-and inflammasome-driven tumor immunity. Cancer Discov. 2019; 9 (12): 1754–1773. doi: 10.1158/2159-8290 XY Li, AK Moesta, C Xiao, K Nakamura, M Casey, H Zhang, J Madore, ... CD-19-0541.[Europe PMC free article][Abstract][CrossRef][Google Scholar], 0 | 10 | |
| Glucocorticoid activation by HSD11B1 limits T cell-driven interferon signaling and response to PD-1 blockade in melanoma LMN Melo, D Herrera-Rios, D Hinze, S Löffek, I Oezel, R Turiello, J Klein, ... Journal for Immunotherapy of Cancer 11 (4), 2023 | 6 | 2023 |
| CD4+ T cell immunity against cutaneous melanoma encompasses multifaceted MHC II–dependent responses EG Bawden, T Wagner, J Schröder, M Effern, D Hinze, L Newland, ... Science immunology 9 (91), eadi9517, 2024 | 1 | 2024 |
| CRISPitope: A generic platform to model target antigens for adoptive T cell transfer therapy in mouse tumor models M Effern, N Glodde, E Bawden, J Liebing, D Hinze, T Tüting, T Gebhardt, ... STAR protocols 3 (1), 101038, 2022 | 1 | 2022 |
| Not sweet: glucocorticoids from intratumoral myeloid cells disable T cells M Effern, M Hölzel Immunity 53 (3), 476-478, 2020 | 1 | 2020 |
| From Tpex to Tex: a journey through CD8+ T cell responses in cancer immunotherapy JM Messmer, M Effern, M Hölzel Signal Transduction and Targeted Therapy 8 (1), 331, 2023 | | 2023 |
| Identifying molecular mechanisms underlying MHC class I downregulation as a resistance mechanism to T cell-based immunotherapy in melanoma H Boll, N Glodde, M Effern, J Liebing, D Hinze, M Hoelzel EXPERIMENTAL DERMATOLOGY 32 (4), E114-E114, 2023 | | 2023 |
| Modelling resistance in melanoma immunotherapy using CRISPR/Cas9 M Effern, N Glodde, J Liebing, M Braun, EG Bawden, D Hinze, ... EXPERIMENTAL DERMATOLOGY 32 (4), E63-E63, 2023 | | 2023 |
| Modelling melanoma control by tissue-resident memory T cells using CRISPR/Cas9 M Effern, EG Bawden, T Wagner, K Hochheiser, N McBain, ... EXPERIMENTAL DERMATOLOGY 32 (4), E62-E62, 2023 | | 2023 |
| Meeting Report: 47th Annual Meeting of the" Arbeitsgemeinschaft Dermatologische Forschung". G Stary, M Fabri, C Gebhardt, R Eming, J Matthias, A Vorobyev, M Effern, ... Experimental dermatology 31 (10), 2022 | | 2022 |
